We live in a rapidly changing world and businesses need to stay agile. Finding ways to lower cost and ad value is on all businesses agenda. Actually doing so is another question. Lundbeck has undertaken several steps to ensure they enable the strategy set. “We want to invest significantly in growth opportunities, maximize the growth potential of our global platform, realize the full potential of our New Products and, based on our neuroscience expertise, continue to invest in R&D and innovation.” (Source: Lundbeck website)
One aspect of that has been to move several functions to a business service center and implement Ariba. In the interview below with Maria Tirsgaard at Lundbeck we hear more about what the changes and implications of those changes has meant for the company. Maria herself has an interesting background combining IT skills with business process development experiences.
Facts about Lundbeck
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain disease. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as Alzheimer’s disease, depression, Parkinson’s disease and psychosis.
Lundbeck employs approximately 5,500 people worldwide, 1,700 of whom are based in Denmark. They have employees in 57 countries, and their products are registered in more than 100 countries. Lundbeck has production facilities in China, Denmark, France and Italy and research centres in Denmark and China. Lundbeck generated core revenue of approximately DKK 13.5 billion in 2014. (Source: Lundbeck website)
To view all slides from Ariba Commerce Summit 2015 in Stockholm, >>click here